etelcalcetide hydrochloride

09/01/2022 - "Recently, we demonstrated the efficacy of etelcalcetide in the control of secondary hyperparathyroidism (SHPT). "
01/01/2021 - "Data on the safety, efficacy of etelcalcetide in children with secondary hyperparathyroidism (sHPT) are limited. "
03/01/2021 - "The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics. "
03/01/2021 - "The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients."
01/01/2021 - "Etelcalcetide is a second-generation calcimimetic for the management of secondary hyperparathyroidism (SHPT) in patients on dialysis. "

01/01/2022 - "Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease."
01/05/2019 - "Etelcalcetide is an intravenous injectable drug that can be administered and eliminated through the dialysis circuit in chronic kidney disease patients. "
11/01/2021 - "A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis."
05/01/2016 - "Key factors anticipated to affect the pharmacokinetics and disposition of etelcalcetide in chronic kidney disease patients on hemodialysis are the drug's intrinsic dialytic properties and biotransformation kinetics. "
11/01/2021 - "This study reports data from the first evaluation of etelcalcetide treatment in Chinese adults with chronic kidney disease and secondary hyperparathyroidism. "

06/01/2017 - "Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients."
01/01/2018 - "Etelcalcetide and its low-molecular-weight transformation products are rapidly cleared by renal excretion in healthy subjects, but clearance is substantially reduced and dependent on hemodialysis in end-stage renal disease. "
07/01/2023 - "This study aimed to evaluate the long-term use etelcalcetide for the treatment of sHPTH (PTH > 600 pg/mL) in patients undergoing extracorporeal hemodialysis for ESRD for at least 2 years. "
01/01/2018 - "Although 30% or more patients with end-stage renal disease are diabetics and about the same percentage of those patients suffer from sHPT associated with hemodialysis, no data on the specificities of the use of etelcalcetide in such patients are available yet. "
01/01/2022 - "Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease."

05/19/2014 - "In the 5/6 Nx chronic uremia model, daily IV dosing of AMG 416 over 4 weeks (1 mg/kg) resulted in a sustained reduction in PTH, with approximately 50% of the initial level observed 48 hours post treatment throughout the study. "
05/19/2014 - "Comparison of AMG 416 and cinacalcet in rodent models of uremia."
05/01/2021 - "Etelcalcetide reduced parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism of uremia in clinical studies. "
05/19/2014 - "This report describes the activity of AMG 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis. "
05/01/2021 - "Etelcalcetide (Parsabiv®, AMG 416/ONO-5163) is a novel allosteric modulator for the calcium-sensing receptor approved for hemodialysis patients with secondary hyperparathyroidism of uremia. "

01/01/2022 - "This is a unique case in which Etelcalcetide treatment is comparable to parathyroidectomy on SHPT and is associated with significant improvement in severe myelofibrosis."